A new genotyping assay for drug metabolism studies is now available to OHSU researchers. Compared to traditional methods, the microassay enables faster discovery and measurement of genetic variation associated with drug response. It includes 1,936 drug metabolism markers in 225 genes and covers more than 90 percent of the current ADME Core markers as defined by the PharmaADME group. This new tool can help investigators discover new biomarker associations, determine drug responders versus non-responders, and identify populations at risk for adverse events.
The assay is provided by the Affymetrix Microarray Core (AMC), a unit of the Gene Microarray Shared Resource at OHSU. The AMC provides RNA Expression Profiling and DNA Variation Analysis services using Affymetrix GeneChip® oligonucleotide arrays.
To find out more about how to access this new resource, contact Chris Harrington at email@example.com.
Learn more about the DMET assay from the Affymetrix website.